Compare Stocks: TNGX, BBIO, EXEL, and BMRN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$74.84 -0.8%	$80.74	$48.78 ▼ $93.42	$14.63B	0.97	2.07 million shs	1.54 million shs
BMRN BioMarin Pharmaceutical	$66.53 +0.2%	$62.58	$49.26 ▼ $70.98	$12.88B	0.24	2.24 million shs	2.30 million shs
EXEL Exelixis	$59.01 -0.2%	$55.07	$33.76 ▼ $59.72	$14.62B	0.42	2.26 million shs	1.58 million shs
TNGX Tango Therapeutics	$22.52 -1.1%	$27.05	$6.25 ▼ $34.39	$3.80B	1.12	2.16 million shs	1.46 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	-0.76%	-2.30%	-8.72%	+10.69%	+44.37%
BMRN BioMarin Pharmaceutical	+0.15%	+2.88%	+11.05%	+17.19%	+12.80%
EXEL Exelixis	-0.20%	+8.37%	+4.07%	+11.97%	+59.66%
TNGX Tango Therapeutics	-1.05%	-3.51%	-21.78%	+11.37%	+236.12%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$74.84 -0.8%	$80.74	$48.78 ▼ $93.42	$14.63B	0.97	2.07 million shs	1.54 million shs
BMRN BioMarin Pharmaceutical	$66.53 +0.2%	$62.58	$49.26 ▼ $70.98	$12.88B	0.24	2.24 million shs	2.30 million shs
EXEL Exelixis	$59.01 -0.2%	$55.07	$33.76 ▼ $59.72	$14.62B	0.42	2.26 million shs	1.58 million shs
TNGX Tango Therapeutics	$22.52 -1.1%	$27.05	$6.25 ▼ $34.39	$3.80B	1.12	2.16 million shs	1.46 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	-0.76%	-2.30%	-8.72%	+10.69%	+44.37%
BMRN BioMarin Pharmaceutical	+0.15%	+2.88%	+11.05%	+17.19%	+12.80%
EXEL Exelixis	-0.20%	+8.37%	+4.07%	+11.97%	+59.66%
TNGX Tango Therapeutics	-1.05%	-3.51%	-21.78%	+11.37%	+236.12%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.83	Moderate Buy	$101.53	35.66% Upside
BMRN BioMarin Pharmaceutical	2.74	Moderate Buy	$89.17	34.04% Upside
EXEL Exelixis	2.35	Hold	$50.07	-15.16% Downside
TNGX Tango Therapeutics	2.75	Moderate Buy	$43.46	92.99% Upside

Current Analyst Ratings Breakdown

Latest TNGX, BBIO, EXEL, and BMRN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	BMRN BioMarin Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
9/2/2026	BBIO BridgeBio Pharma	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/2/2026	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
9/1/2026	BBIO BridgeBio Pharma	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$96.00 ➝ $110.00
9/1/2026	BMRN BioMarin Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$88.00 ➝ $90.00
9/1/2026	EXEL Exelixis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/31/2026	BMRN BioMarin Pharmaceutical	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$104.00 ➝ $105.00
8/31/2026	BMRN BioMarin Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$59.00 ➝ $60.00
8/26/2026	BMRN BioMarin Pharmaceutical	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$88.00
8/19/2026	BMRN BioMarin Pharmaceutical	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$98.00
8/18/2026	EXEL Exelixis	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$54.00

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$502.08M	29.14	N/A	N/A	($12.81) per share	-5.84
BMRN BioMarin Pharmaceutical	$3.22B	4.00	$2.85 per share	23.32	$32.66 per share	2.04
EXEL Exelixis	$2.32B	6.30	$3.03 per share	19.49	$7.44 per share	7.93
TNGX Tango Therapeutics	$53.81M	70.56	N/A	N/A	$6.08 per share	3.70

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$724.93M	-$3.57	N/A	N/A	N/A	-97.03%	N/A	-61.19%	10/28/2026 (Estimated)
BMRN BioMarin Pharmaceutical	$348.90M	$0.37	179.81	12.21	0.48	2.14%	5.32%	3.69%	10/26/2026 (Estimated)
EXEL Exelixis	$782.57M	$3.18	18.56	15.86	1.76	35.33%	42.17%	31.76%	11/3/2026 (Estimated)
TNGX Tango Therapeutics	-$101.59M	-$0.85	N/A	N/A	N/A	N/A	-25.75%	-23.36%	11/3/2026 (Estimated)

Latest TNGX, BBIO, EXEL, and BMRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	TNGX Tango Therapeutics	-$0.3172	-$0.37	-$0.0528	-$0.37	$1.56 million	N/A
8/10/2026	Q2 2026	BBIO BridgeBio Pharma	-$0.5756	-$0.78	-$0.2044	-$0.78	$220.91 million	$243.68 million
8/6/2026	Q2 2026	BMRN BioMarin Pharmaceutical	$0.95	$1.20	+$0.25	$0.23	$932.03 million	$989.71 million
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	1.23	1.17
BMRN BioMarin Pharmaceutical	0.56	2.39	1.32
EXEL Exelixis	N/A	3.46	3.38
TNGX Tango Therapeutics	N/A	50.82	50.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
BMRN BioMarin Pharmaceutical	98.71%
EXEL Exelixis	85.27%
TNGX Tango Therapeutics	78.99%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	14.23%
BMRN BioMarin Pharmaceutical	0.68%
EXEL Exelixis	2.60%
TNGX Tango Therapeutics	6.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	195.49 million	167.67 million	Optionable
BMRN BioMarin Pharmaceutical	3,221	193.57 million	192.26 million	Optionable
EXEL Exelixis	1,077	247.78 million	241.34 million	Optionable
TNGX Tango Therapeutics	90	168.61 million	157.65 million	Optionable

TNGX, BBIO, EXEL, and BMRN Headlines

Recent News About These Companies

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 3 at 4:05 PM | globenewswire.com

390,920 Shares in Tango Therapeutics, Inc. $TNGX Acquired by Bank of New York Mellon Corp

September 2 at 3:28 AM | marketbeat.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Recommendation of "Moderate Buy" by Brokerages

September 2 at 1:45 AM | americanbankingnews.com

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

September 1, 2026 | globenewswire.com

181,212 Shares in Tango Therapeutics, Inc. $TNGX Purchased by The Manufacturers Life Insurance Company

September 1, 2026 | marketbeat.com

Alyeska Investment Group L.P. Increases Holdings in Tango Therapeutics, Inc. $TNGX

September 1, 2026 | marketbeat.com

Nantahala Capital Management LLC Takes Position in Tango Therapeutics, Inc. $TNGX

August 29, 2026 | marketbeat.com

Jefferies Financial Group Inc. Makes New Investment in Tango Therapeutics, Inc. $TNGX

August 28, 2026 | marketbeat.com

Oxford Nanopore Technologies (OTCMKTS:ONTTF) vs. Tango Therapeutics (NASDAQ:TNGX) Head to Head Contrast

August 28, 2026 | americanbankingnews.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of "Moderate Buy" by Brokerages

August 28, 2026 | marketbeat.com

Seven Fleet Capital Management LP Raises Stock Position in Tango Therapeutics, Inc. $TNGX

August 27, 2026 | marketbeat.com

Jupiter Topco LLC Invests $157.99 Million in Tango Therapeutics, Inc. $TNGX

August 27, 2026 | marketbeat.com

Boone Capital Management LLC Invests $14.24 Million in Tango Therapeutics, Inc. $TNGX

August 27, 2026 | marketbeat.com

Algert Global LLC Grows Position in Tango Therapeutics, Inc. $TNGX

August 27, 2026 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Trading Up 4.8% - Here's Why